Background: Cardiac sarcoidosis (CS) is a noncaseating granulomatous disease of
| INTRODUCTION
Sarcoidosis is a systemic inflammatory and noncaseating granulomatous disease, involving various organs such as the lungs, eyes, heart, skin, lymph node, and nerves. 1 Although the etiology of sarcoidosis remains unknown, a hypersensitivity of immune reaction has been suspected as the main cause of sarcoidosis. 2 Cardiac sarcoidosis (CS) has been reported more frequently in Japan compared with other countries. 3, 4 CS is an important predictor of poor prognosis in sarcoidosis due to advanced heart failure and various severe fatal arrhythmias such as atrioventricular block, ventricular tachycardia, and ventricular fibrillation.
5-10
The standard treatment for CS involves immunosuppressive therapy with corticosteroids, administered to control the hypersensitivity of immune reaction, 11, 12 prevent inflammation and fibrosis, and protect from deterioration of cardiac function. Previous studies revealed that long-term treatment with corticosteroids exerts a favorable effect on CS, 13 whereas discontinuation of corticosteroid therapy results in poor prognosis for CS. 14 
| Study design
The patients will be randomized in a 1:1 ratio to receive either standard corticosteroid therapy plus ABD therapy (ABD group) or standard corticosteroid therapy (standard group). The time course of this study is shown in Figure 1 .
Randomization will be performed using a web-based validated system (tsClinical DDworks21/EDC plus, FUJITSU LIMITED, Japan), to adverse events at 6 and 12 months, as well as the frequency of skin rash, diarrhea, and lethal arrhythmia at 6 and 12 months.
The study protocol must be approved by all participating institutions. All participants are required to provide written informed consent (M28-110, Dec 12, 2016).
| Study population
Patients with CS, in need of de novo corticosteroid therapy, will be 
| Sample size calculation
As data regarding ABD therapy in addition to corticosteroid therapy for patients with CS are limited, it is not possible to predetermine the required sample size for this study. Thus, the study was designed to enroll a minimum of 80 patients and perform an interim analysis for sample size recalculation based on the observed data. Primary endpoint change in the total SUV at 6 mo versus baseline using FDG-PET/CT Secondary endpoints frequency of corticosteroid dose escalation change in total SUV at 12 mo versus baseline using FDG-PET/CT change in maximum and mean SUV at 6 and 12 mo vs baseline using FDG-PET/CT a composite of MACE (cardiovascular death, lethal arrhythmia, and hospitalization for heart failure) change in LVEF at 6 and 12 mo vs baseline using echocardiography change of ACE, lysozyme, and sIL-2R levels at 6 and 12 mo vs baseline rate reduction in ACNEX at 6 and 12 mo vs baseline rate of adverse event occurrence, drug discontinuation, skin rash, diarrhea, and lethal arrhythmia The schedule for the administration of standard therapy is shown in Figure 2B . The administration of corticosteroid therapy is identical to that of the ABD group.
| Dose escalation of corticosteroid therapy
Dose escalation of corticosteroid therapy is based on the following criteria: (i) improvement of <10% in the maximum SUV at study visits vs baseline using FDG-PET/CT, (ii) decrease in ≥10% in LVEF at | 523 follow-up vs baseline using echocardiography, (iii) thinning or thickening of the ventricular wall occurring or worsening using echocardiography, (iv) increase in serum markers (sIL-2R, ACE, and lysozyme), and (v) decision by the expert committee of this study.
| Study visits
Study visits will be scheduled at 2, 4, 8, 12, 24, 32, 40, and 48 weeks and at 2, 3, 4, and 5 years after administration of treatment. During these visits, drug management, standard blood examinations, 12-lead electrocardiograms, collection of data on the concomitant usage of drugs, recording of treatment-related adverse effects, and/or clinical events including MACE will be performed.
Vital data and special blood examinations will be performed at 12 weeks. In addition, chest X-ray, echocardiography, 24-h Holter electrocardiogram (ECG) monitoring, and FDG-PET/CT will be performed at 24 and 48 weeks, and at 2, 3, 4, and 5 years.
| Evaluations
Patient baseline characteristics and the status of medical treatment for each group are shown in Table 1 . Follow-up data for each group are presented in Table 2 .
Data will be shared using only a specific ID number allocated to protect the identity of patients. The protocol of this study will be approved by the Ethics Committee of each institution and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices. Informed consent will be obtained from the patients and/or their legal guardians.
| Monitoring
At each visit, the principal investigator (PI) or investigator will interview the patient. When an adverse event occurs, the PI or investigator will follow up with the patient until the AE resolves and will input the data into the website.
In this trial, the data monitoring committee will perform a central monitoring of the data stored on the website. The data monitoring committee is independent of the investigators.
| Data quality control and management
The PI or investigator must follow the instructions of this study protocol. The PI and investigator cannot modify the protocol without permission by the ethics committees at each center. When a deviation from the protocol occurs, the PI or investigator must record everything.
When new data requiring revision of the protocol are identified and the data monitoring committee recommends the revision, the representative investigator of this trial will revise the protocol. The revision of the protocol must be approved by the ethics committees at each center. 24-h Holter ECG monitoring Ventricular tachycardia, n (%), mean heart rate, bpm, max heart rate, bpm, minimum heart rate, bpm, premature ventricular contraction, n (%), premature supraventricular contraction, n (%), atrial fibrillation, n (%), atrioventricular block, n (%), sinus pause ≧2. Mean SUV, total SUV, the dispersion value of SUV, the coefficient of variation in SUV Concomitant drug use ACE inhibitor and/or ARB, n (%), beta blocker, n (%), anti-arrhythmic drug, n (%), antihypertensive drug, n (%), other kind of drug, n (%)
Combination therapy
Pacemaker, n (%), ICD, n (%), CRT-P, n (%), CRT-D, n (%), other combination therapy, n (%) ACE, angiotensin-converting-enzyme; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; CRP, C-reactive protein; CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; ECG, electrocardiogram; FBS, fasting blood sugar; FDG-PET/CT, fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography; FT4, free thyroxine; Hb, hemoglobin; ICD, implantable cardioverter-defibrillator; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; sIL-2R, soluble interleukin-2 receptor; SUV, standardized uptake value; TSH, thyroid stimulating hormone; WBC, white blood cell.
| Statistical analysis
The appropriate combination pattern, administration period, and frequency of adverse effects of ABD therapy for CS remain unclear.
Therefore, the efficacy and safety of ABD therapy, in addition to corticosteroid therapy, for the treatment of CS are assessed in this study.
| CONCLUSION
The J-ACNES trial will be the first prospective investigation assessing the clinical benefit and safety of ABD therapy, in addition to corticosteroid therapy, for the treatment of patients with CS. These findings may improve the treatment of patients with CS, as additional ABD therapy reduces the recurrence of inflammation and elucidates the mechanism of sarcoidosis.
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